P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE

• Jeffrey Rubnitz,
• Ghayas C. Issa,
• Eytan M. Stein,
• Neerav Shukla,
• Wendy Stock,
• Andrius Žučenka,
• Sajad Khazal,
• Nandita Khera,
• Elliot Stieglitz,
• Jeremy Rubinstein,
• Galit Rosen,
• Rachel Ghiraldi,
• Huy Van Nguyen,
• Nicole Mcneer,
• C. Michel Zwaan

Affiliations

Jeffrey Rubnitz

1 St. Jude Children’s Research Hospital, Memphis, TN, United States

Ghayas C. Issa

2 The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Eytan M. Stein

3 Memorial Sloan Kettering Cancer Center, New York, NY, United States

Neerav Shukla

3 Memorial Sloan Kettering Cancer Center, New York, NY, United States

Wendy Stock

4 University of Chicago, Chicago, IL, United States

Andrius Žučenka

5 Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

Sajad Khazal

2 The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Nandita Khera

7 The Mayo Clinic, Phoenix, AZ, United States

Elliot Stieglitz

8 The University of California, San Francisco, San Francisco, CA, United States

Jeremy Rubinstein

9 Cincinatti Children’s Hospital, Cincinnati, OH, United States

Galit Rosen

10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States

Rachel Ghiraldi

10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States

Huy Van Nguyen

10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States

Nicole Mcneer

10 Syndax Pharmaceuticals, Inc., Waltham, MA, United States

C. Michel Zwaan

11 Princess Máxima Center, Utrecht, and Erasmus MC, Rotterdam, The Netherlands